Bullous skin disorders associated with PD-1 and PDL-1 inhibitors: Pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) from the Research on Adverse Drug events And Reports (RADAR) Program - 22/08/19
Javier Jimenez, MD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Beatrice Nardone, MD, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Cory Kosche, BS, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Corinne Rauck, BA, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Stephanie M. Rangel, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Dennis P. West, PhD, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL; Mario E, Lacouture, MD, Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Le texte complet de cet article est disponible en PDF. Commercial support: None identified. |
Vol 81 - N° 4S1
P. AB29 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?